Evidence map›Paper›PMID 32428990›Full record

ArticleEMBO molecular medicine2020

The role of interleukin-6 in monitoring severe case of coronavirus disease 2019.

Tao Liu, Jieying Zhang, Yuhui Yang, Hong Ma, Zhenyu Li, Jiaoyue Zhang, Ji Cheng, Xiaoyun Zhang, Yanxia Zhao, Zihan Xia and 3 more

2 registry-linked trialsOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EMBO molecular medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 247 papers, 13 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
247citing papers in PubMed, 13 pooled it
8.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04514627 nacompletednot on this map

Neuromodulation With Percutaneous Electrical Nerve Field Stimulation for Adults With COVID-19

TypeinterventionalSponsorOlive View-UCLA Education & Research InstituteRan2020 to 2022Enrolled55ConditionsCOVID-19ArmsAuricular percutaneous neurostimulation
NCT05062681 phase4unknown statusnot on this mapstarted 2021, after this paper: background citation

Randomized Controlled Trial on the Efficacy of Dexamethasone Versus Methyl Prednisolone in Covid-19 Infected Patients With High Oxygen Flow

TypeinterventionalSponsorCairo UniversityRan2021 to 2022Enrolled60ConditionsCOVID-19 PandemicArmsDexamethasone, Methylprednisolone
3 · Its place in the literature

Who cites it

247 citing papers in PubMed, 13 syntheses or guidelines pooled it, 409 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Effect of high-doseFrontiers in immunology · 2024
    Trial
  15. Trial
  16. Trial
  17. Trial
  18. Article
  19. Article
  20. Article

187 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Tao Liu *Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.ORCID 0000-0002-4340-5767
Jieying Zhang *Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Yuhui Yang *Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Hong MaCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Zhenyu LiCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Jiaoyue ZhangDepartment of Endocrinology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Ji ChengDepartment of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Xiaoyun ZhangLiver intensive care unit, Zhongshan Hospital, Fudan University, Shanghai, China.
Yanxia ZhaoCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Zihan XiaCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Liling ZhangCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.ORCID 0000-0002-0198-2603
Gang WuCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.ORCID 0000-0002-9843-7336
Jianhua YiDepartment of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.ORCID 0000-0001-8883-6360
Wuhan Union Hospital · CNFudan University · CNUnion Hospital · CN

Funding

Fundamental Research Funds for Central Universities of the Central South University (Fundamental Research Funds for the Central Universities of the Central South University) 2015QN190The National Natural Science Foundation of China 81602696The National Science and Technology Major Project of China 2018ZX10302204-002-003
6 · The paper itself

Abstract

Progression to severe disease is a difficult problem in treating coronavirus disease 2019 (COVID-19). The purpose of this study is to explore changes in markers of severe disease in COVID-19 patients. Sixty-nine severe COVID-19 patients were included. Patients with severe disease showed significant lymphocytopenia. Elevated level of lactate dehydrogenase (LDH), C-reactive protein (CRP), ferritin, and D-dimer was found in most severe cases. Baseline interleukin-6 (IL-6) was found to be associated with COVID-19 severity. Indeed, the significant increase of baseline IL-6 was positively correlated with the maximal body temperature during hospitalization and with the increased baseline of CRP, LDH, ferritin, and D-dimer. High baseline IL-6 was also associated with more progressed chest computed tomography (CT) findings. Significant decrease in IL-6 and improved CT assessment was found in patients during recovery, while IL-6 was further increased in exacerbated patients. Collectively, our results suggest that the dynamic change in IL-6 can be used as a marker for disease monitoring in patients with severe COVID-19.

Indexed as

AdultAgedAged, 80 and overAntiviral AgentsBetacoronavirusBiomarkersCoronavirus InfectionsCOVID-19C-Reactive ProteinFemaleHumansInterleukin-6LymphopeniaMaleMiddle AgedPandemicsAntiviral AgentsBiomarkersC-Reactive ProteinInterleukin-6biomarkercoronavirus disease 2019cytokine stormdisease monitoringinterleukin-6

Identifiers

PMID32428990
PMCPMC7280589
OpenAlexW3025830962

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.